This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ASCO GU 2023
ASCO GU 2023
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Carcinoma
Press Releases
Penile, Urethral, Testicular, and Adrenal Cancers
ASCO GU 2023 Prostate Cancer
Viewing 1-20 of 95 articles
ASCO GU 2023: Identifying Prostate Cancer Patient Subgroups Based on Their Preferences for Key Attributes of Androgen Deprivation Therapies
ASCO GU 2023: Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2023: 18F-DCFPyL PET in First Biochemical Recurrence and Initial Staging: Concordance with Conventional Imaging
ASCO GU 2023: Radium-223 for mCRPC, a Real-World Experience Study from 7 Galician Medical Centers
ASCO GU 2023: Patterns of Failure After Radiotherapy in Patients with Prostate Cancer Re-Staged with 18F-DCFPyL PSMA-PET: A Regional Cohort Analysis
ASCO GU 2023: Lutetium-177 PSMA Radioligand Therapy for mCRPC in Germany: Population-Based Data with Multicenter Validation from 2016 to 2020
ASCO GU 2023: Predictive and Prognostic Potential of Pretreatment 68Ga-PSMA PET Tumor Heterogeneity Index in Patients with mCRPC
ASCO GU 2023: Socioeconomic Vulnerability and the Risk of Genitourinary Cancer Mortality Among United States Counties
ASCO GU 2023: Evaluation of ctDNA in Patients Treated with Lutetium-177-PSMA-617
ASCO GU 2023: Ending Cancer as We Know It: Predicting Future Cancer Progress
ASCO GU 2023: Patient Perspective on Fatigue and Its Management for Advanced Prostate Cancer Treated with Androgen Receptor Inhibitors (ARIs)
ASCO GU 2023: Prognostic Biomarkers and Clinical Outcomes in Neuroendocrine Prostate Cancer (NEPC)
ASCO GU 2023: Genomic Alterations in Patients with Prostate Cancer with Liver Metastases
ASCO GU 2023: Early Outcomes from Lutetium Lu-177 Vipivotide Tetraxetan Treatment in Patients Selected for Therapy with Piflufolastat F-18 PET Imaging
ASCO GU 2023: Use of a Navigable Interface for Integrated Whole Genome and Transcriptome Sequencing as a Platform for Pursuit of Therapeutic Targets in Advanced Prostate Cancers
ASCO GU 2023: The Impact of Genomic Biomarkers on a Validated Clinical Risk Prediction Model for Upgrading/upstaging Among Men with Low-Risk Prostate Cancer
ASCO GU 2023: Ability of STAR-CAP Staging System to Prognosticate Risk of Subsequent Therapies After Initial Treatment of M0 Prostate Cancer
ASCO GU 2023: The Impact of F-18 PSMA PET Imaging on Clinical Decision-Making in Prostate Cancer Across Disease States
ASCO GU 2023: Patterns of Failure with 18F-DCFPyL PSMA PET/CT in the Post-Prostatectomy Setting: A Regional Cohort Analysis
ASCO GU 2023: NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy with or Without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)
1
2
3
4
5
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free